International audienceThere is room for improvement in the algorithms used in closed-loop insulin therapy during the prandial period. This pilot study evaluated the efficacy and safety of the Diabeloop algorithm (model predictive control type) during the postprandial period.This 2-center clinical trial compared interstitial glucose levels over two 5-hour periods (with/without the algorithm) following a calibrated lunch. On the control day, the amount of insulin delivered by the pump was determined according to the patient’s usual parameters. On the test day, 50% or 75% of the theoretical bolus required was delivered, while the algorithm, informed of carbohydrate intake, proposed changes to insulin delivery every 15 minutes using modeling to...
AIMS: To evaluate safety, efficacy and glucose turnover during closed-loop with meal announcement us...
In this thesis I propose a novel method to estimate the dose and injection-to-meal time for low-risk...
INTRODUCTION: Despite therapeutic advances, many people with type 1 diabetes are still unable to ach...
International audienceThere is room for improvement in the algorithms used in closed-loop insulin th...
International audienceBackground: The purpose was to assess the efficacy of a new closed-loop algori...
With the discovery of insulin came a deeper understanding of therapeutic options for one of the most...
INTRODUCTION: Manual determination of insulin dosing largely fails to optimise glucose control in ty...
OBJECTIVETo compare two validated closed-loop (CL) algorithms versus patient self-control with CSII ...
OBJECTIVE: To compare two validated closed-loop (CL) algorithms versus patient self-control with CSI...
Type 1 diabetes-mellitus implies a life-threatening absolute insulin deficiency. Artificial pancrea...
New effort has been made to develop closed-loop glucose control, using subcutaneous (SC) glucose sen...
OBJECTIVE: To compare the safety and efficacy of overnight closed loop delivery of insulin (artifici...
The aim of this pilot study was to test the feasibility of a bihormonal (glucagon and insulin) close...
Background: In type 1 diabetes therapy, precise tuning of postprandial corrective insulin boluses (C...
OBJECTIVEdTo compare two validated closed-loop (CL) algorithms versus patient selfcontrol with CSII ...
AIMS: To evaluate safety, efficacy and glucose turnover during closed-loop with meal announcement us...
In this thesis I propose a novel method to estimate the dose and injection-to-meal time for low-risk...
INTRODUCTION: Despite therapeutic advances, many people with type 1 diabetes are still unable to ach...
International audienceThere is room for improvement in the algorithms used in closed-loop insulin th...
International audienceBackground: The purpose was to assess the efficacy of a new closed-loop algori...
With the discovery of insulin came a deeper understanding of therapeutic options for one of the most...
INTRODUCTION: Manual determination of insulin dosing largely fails to optimise glucose control in ty...
OBJECTIVETo compare two validated closed-loop (CL) algorithms versus patient self-control with CSII ...
OBJECTIVE: To compare two validated closed-loop (CL) algorithms versus patient self-control with CSI...
Type 1 diabetes-mellitus implies a life-threatening absolute insulin deficiency. Artificial pancrea...
New effort has been made to develop closed-loop glucose control, using subcutaneous (SC) glucose sen...
OBJECTIVE: To compare the safety and efficacy of overnight closed loop delivery of insulin (artifici...
The aim of this pilot study was to test the feasibility of a bihormonal (glucagon and insulin) close...
Background: In type 1 diabetes therapy, precise tuning of postprandial corrective insulin boluses (C...
OBJECTIVEdTo compare two validated closed-loop (CL) algorithms versus patient selfcontrol with CSII ...
AIMS: To evaluate safety, efficacy and glucose turnover during closed-loop with meal announcement us...
In this thesis I propose a novel method to estimate the dose and injection-to-meal time for low-risk...
INTRODUCTION: Despite therapeutic advances, many people with type 1 diabetes are still unable to ach...